| Trial ID: | L4103 |
| Source ID: | NCT01357135
|
| Associated Drug: |
Metformin
|
| Title: |
An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01357135/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Metformin|DRUG: Sitagliptin|DRUG: Sulfonylurea|DRUG: Antihyperglycemic Medication
|
| Outcome Measures: |
Primary: Median Duration (in Months) of Initial Dual Therapy, The treatment maintenance duration corresponds to the treatment maintenance and persistence duration for dual therapy combining the same agents. Withdrawal of an agent, replacement of one agent by another or addition of a third agent is perceived as a change in treatment and, hence, the end of the treatment maintenance duration for dual therapy., Up to 3 years|Percentage of Participants With Strict Changes in Initial Dual Therapy, Strict changes in dual therapy were defined as withdrawal of an agent, replacement of one agent by another, or the addition of a third agent. Changes in dose level were not considered strict changes., Up to 3 years |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
3453
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2009-07-15
|
| Completion Date: |
2013-08-31
|
| Results First Posted: |
2014-12-05
|
| Last Update Posted: |
2017-06-05
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT01357135
|
